Journal Article
. 2013 Dec;14(12).
doi: 10.3390/ijms141223685.

Prognostic discrimination using a 70-gene signature among patients with estrogen receptor-positive breast cancer and an intermediate 21-gene recurrence score

Sung Gwe Ahn 1 Hak Min Lee  Hak Woo Lee  Seung Ah Lee  Se-Ra Lee  Sun-Hee Leem  Joon Jeong  In-Sun Chu  
Affiliations
  • PMID: 24304542
  •     25 References
  •     9 citations

Abstract

The Oncotype DX® recurrence score (RS) predictor has been clinically utilized to appropriately select adjuvant chemotherapy for patients with estrogen receptor (ER)-positive early breast cancer. However, the selection of chemotherapy for patients with intermediate RSs remains controversial. We assessed the prognostic value of a 70-gene signature (70GS) among patients with ER-positive breast cancer and intermediate RSs. In addition, we sought to identify genes associated with poor 70GS scores based on gene expression profiling (GEP). GEP was performed using gene expression data from 186 patients with ER-positive breast cancer. The RS and 70GS score were calculated on the basis of GEP. Among 186 patients, 82 ER-positive patients with intermediate RSs were identified. These patients were stratified by 70GS, overall survival (OS) significantly differed according to 70GS (p=0.013). In a supervised hierarchical analysis according to 70GS, the expression of several representative genes for cell proliferation was significantly higher in the poor 70GS cluster than in the good 70GS cluster. Furthermore, among these patients, FOXM1, AURKA, AURKB, and BIRC5 displayed prognostic significance for OS. In conclusion, 70GS can help to discriminate survival differences among ER-positive patients with intermediate RSs. FOXM1, AURKA, AURKB, and BIRC5, are associated with poor 70GS scores.

Gene expression profiling predicts clinical outcome of breast cancer.
Laura J van 't Veer, Hongyue Dai, +13 authors, Stephen H Friend.
Nature, 2002 Feb 02; 415(6871). PMID: 11823860
Highly Cited.
FOX(M1) news--it is cancer.
Marianna Halasi, Andrei L Gartel.
Mol Cancer Ther, 2013 Feb 28; 12(3). PMID: 23443798    Free PMC article.
Highly Cited. Review.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
A Howell, J Cuzick, +8 authors, ATAC Trialists' Group.
Lancet, 2005 Jan 11; 365(9453). PMID: 15639680
Highly Cited.
Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data.
Christian Pilarsky, Michael Wenzig, +2 authors, Robert Grützmann.
Neoplasia, 2005 Feb 22; 6(6). PMID: 15720800    Free PMC article.
Highly Cited.
Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival.
Howard Y Chang, Dimitry S A Nuyten, +10 authors, Marc J van de Vijver.
Proc Natl Acad Sci U S A, 2005 Feb 11; 102(10). PMID: 15701700    Free PMC article.
Highly Cited.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe.
Diane R Wonsey, Maximillian T Follettie.
Cancer Res, 2005 Jun 17; 65(12). PMID: 15958562
Highly Cited.
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
Raimund Jakesz, Walter Jonat, +12 authors, ABCSG and the GABG.
Lancet, 2005 Aug 09; 366(9484). PMID: 16084253
Highly Cited.
Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer.
Britta Weigelt, Zhiyuan Hu, +6 authors, Laura J Van't Veer.
Cancer Res, 2005 Oct 19; 65(20). PMID: 16230372
Highly Cited.
Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase.
I-Ching Wang, Yi-Ju Chen, +6 authors, Robert H Costa.
Mol Cell Biol, 2005 Nov 30; 25(24). PMID: 16314512    Free PMC article.
Highly Cited.
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.
Christos Sotiriou, Pratyaksha Wirapati, +17 authors, Mauro Delorenzi.
J Natl Cancer Inst, 2006 Feb 16; 98(4). PMID: 16478745
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
Marc Buyse, Sherene Loi, +18 authors, TRANSBIG Consortium.
J Natl Cancer Inst, 2006 Sep 07; 98(17). PMID: 16954471
Highly Cited.
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
Jolien M Bueno-de-Mesquita, Wim H van Harten, +19 authors, Sabine C Linn.
Lancet Oncol, 2007 Nov 29; 8(12). PMID: 18042430
Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer.
Nuran Bektas, Anette ten Haaf, +5 authors, Edgar Dahl.
BMC Cancer, 2008 Feb 08; 8. PMID: 18254960    Free PMC article.
The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.
Stella Mook, Marjanka K Schmidt, +10 authors, TRANSBIG Consortium.
Breast Cancer Res Treat, 2008 Jul 29; 116(2). PMID: 18661261
A conserved phosphorylation site within the forkhead domain of FoxM1B is required for its activation by cyclin-CDK1.
Yi-Ju Chen, Carmen Dominguez-Brauer, +5 authors, Pradip Raychaudhuri.
J Biol Chem, 2009 Sep 10; 284(44). PMID: 19737929    Free PMC article.
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer.
Marieke E Straver, Annuska M Glas, +7 authors, Sjoerd Rodenhuis.
Breast Cancer Res Treat, 2009 Feb 14; 119(3). PMID: 19214742
The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age.
S Mook, M K Schmidt, +7 authors, L J van 't Veer.
Ann Oncol, 2009 Oct 15; 21(4). PMID: 19825882
New developments in hormone receptor-positive disease.
Martine J Piccart-Gebhart.
Oncologist, 2010 Dec 16; 15 Suppl 5. PMID: 21138952
FoxM1: a master regulator of tumor metastasis.
Pradip Raychaudhuri, Hyun Jung Park.
Cancer Res, 2011 Jun 30; 71(13). PMID: 21712406    Free PMC article.
Highly Cited.
Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53.
E K A Millar, P H Graham, +10 authors, R L Sutherland.
Br J Cancer, 2011 Jun 30; 105(2). PMID: 21712826    Free PMC article.
Comprehensive molecular portraits of human breast tumours.
Cancer Genome Atlas Network.
Nature, 2012 Sep 25; 490(7418). PMID: 23000897    Free PMC article.
Highly Cited.
A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, +18 authors, René Bernards.
N Engl J Med, 2002 Dec 20; 347(25). PMID: 12490681
Highly Cited.
The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells.
Anna Bergamaschi, Zeynep Madak-Erdogan, +3 authors, Benita S Katzenellenbogen.
Breast Cancer Res, 2014 Sep 13; 16(5). PMID: 25213081    Free PMC article.
The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set.
Heloisa Helena Milioli, Renato Vimieiro, +3 authors, Pablo Moscato.
PLoS One, 2015 Jul 02; 10(7). PMID: 26132585    Free PMC article.
Prognostic Value of FOXM1 in Patients with Malignant Solid Tumor: A Meta-Analysis and System Review.
Jun Dai, Lili Yang, +2 authors, Qiurong Ruan.
Dis Markers, 2015 Oct 10; 2015. PMID: 26451068    Free PMC article.
Review.
The Role of Forkhead Box Protein M1 in Breast Cancer Progression and Resistance to Therapy.
Raya Saba, Alhareth Alsayed, James P Zacny, Arkadiusz Z Dudek.
Int J Breast Cancer, 2016 Mar 05; 2016. PMID: 26942015    Free PMC article.
Review.
Aurora A is a prognostic marker for breast cancer arising in BRCA2 mutation carriers.
Margret Aradottir, Sigridur T Reynisdottir, +5 authors, Sigridur K Bodvarsdottir.
J Pathol Clin Res, 2015 Jan 01; 1(1). PMID: 27499891    Free PMC article.
Molecular Classification of Triple-Negative Breast Cancer.
Sung Gwe Ahn, Seung Jun Kim, Cheungyeul Kim, Joon Jeong.
J Breast Cancer, 2016 Oct 11; 19(3). PMID: 27721871    Free PMC article.
Review.
Accelerated parallel algorithm for gene network reverse engineering.
Jing He, Zhou Zhou, Michael Reed, Andrea Califano.
BMC Syst Biol, 2017 Sep 28; 11(Suppl 4). PMID: 28950860    Free PMC article.
A six-long non-coding RNAs signature as a potential prognostic marker for survival prediction of ER-positive breast cancer patients.
Lei Zhong, Ge Lou, +3 authors, Wenqian Jiang.
Oncotarget, 2017 Oct 06; 8(40). PMID: 28978079    Free PMC article.
Precision Medicine for Acute Kidney Injury (AKI): Redefining AKI by Agnostic Kidney Tissue Interrogation and Genetics.
Krzysztof Kiryluk, Andrew S Bomback, +5 authors, Jonathan Barasch.
Semin Nephrol, 2018 Jan 03; 38(1). PMID: 29291761    Free PMC article.
Review.